Since improving patient survival is the main goal in cancer treatment, further meta-analysis evaluation on the combination of markers involved in this critical network including RAS and PTEN with BRAF seems necessary for future planning in cancer treatment and drug development. The gene discussed is PTEN; the disease is cancer.